Skip to main content
SpringerLink
Log in

EGFR-TK-guided therapy not cost effective in NSCLC

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. funded by Covance Inc., UK.

Reference

  • Patel K, et al. A cost-effectiveness analysis of EGFR-TK mutation status-guided 1st- and 2nd-line treatment of stage III/IV non-small cell lung cancer in the UK. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PCN123, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39695.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

EGFR-TK-guided therapy not cost effective in NSCLC. PharmacoEcon Outcomes News 717, 19 (2014). https://doi.org/10.1007/s40274-014-1744-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1744-8

Search

Navigation